Physician profile
William Rees
NPI 1275540320
$656.81
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $194 · 2021: $145 · 2022: $49.77.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $150.71 | 2019-2021 | |
| Pfizer INC. | $125.69 | 2019-2022 | |
| Glaxosmithkline, LLC. | $112.72 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $75.44 | 2019-2021 | |
| Biofire Diagnostics, LLC | $49.20 | 2019 | |
| Sanofi Pasteur INC. | $47.71 | 2019-2020 | |
| Sobi, INC | $35.57 | 2019-2020 | |
| Cranial Technologies, INC | $24.69 | 2019 | |
| Shire North American Group INC | $20.51 | 2019 | |
| Ironshore Pharmaceuticals INC. | $14.57 | 2020 |
6 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Rees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.